期刊文献+

长江流域6城市2005―2007年抗真菌药物应用情况分析 被引量:3

Application of antifungal agents in 6 cities of Yangtze River valley from 2005 to 2007
原文传递
导出
摘要 目的评价长江流域6城市2005―2007年抗真菌药物利用情况。方法收集长江流域6城市157家医院2005―2007年抗真菌药物应用数据,进行金额及用药频度(DDDs)统计分析,对用药金额和DDDs进行排序。结果2005―2007年6城市抗真菌药物用药总金额有所增加,三唑类增幅最大,棘白菌素类增长率最高。金额前2位是氟康唑与伊曲康唑,DDDs前2位是伊曲康唑与特比萘芬;进口药及合资药占据70%以上市场,国产药比例逐年下降。结论2005―2007年长江流域6城市抗真菌药物用药金额呈增长趋势,三唑类增长最明显。 AIM To investigate the application of antifungal agents in 6 cities of Yangtze River lrom 2005 to 2007. METHODS Application of antifungal agents in 157 hospitals of 6 cities from 2005 - 2007 were analyzed according to the orders of sum and DDDs in the databases of each city. RESULTS The total cost of antifungal agents used in 6 cities increased with an annual growth rate of 29.23% from 2005 to 2007. Chongqing ranked high in 6 cities with an annual growth rate of 38.53%. The sum of triazole was the highest. The increase rate of echinocandina, a new type of antifungal agent, was the largest. Fluconazol and itraconazole were in the top of sum. Itraconazole and terbinafine were in the top of DDDs. Over 70% were imported and joint venture products and the domestic drugs decreased year by year. CONCLUSION The sum of antifungal agents, especially the triazole, appears increasing trend in 6 cities of Yangtze River valley.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2009年第10期785-790,共6页 Chinese Journal of New Drugs and Clinical Remedies
关键词 抗真菌药物 药物利用 经济学 药物 长江流域 antifungal agents drug utilization economics, pharmaceutical Yangtze River valley
  • 相关文献

参考文献5

二级参考文献44

  • 1胡庆丰,吕火祥,丁玎.252株深部真菌的鉴定和耐药性分析[J].浙江临床医学,2004,6(7):579-579. 被引量:1
  • 2周竹超,倪泉兴,吴菊芳,章强强.普外科真菌感染84例临床调查[J].中国抗感染化疗杂志,2004,4(4):219-222. 被引量:11
  • 3王倩,郭毅,褚云卓,邓宇欣.应用氟康唑对丹麦ROSCO公司与美国临床实验室标准化委员会酵母菌纸片扩散法药敏试验比较分析[J].中华检验医学杂志,2005,28(12):1304-1306. 被引量:4
  • 4MF, NICHETTI F, del FAVERO A, MARTINO P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenie patients with hemalologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial[J]. Clin Infect Dis, 1999, 28(2) :250-255.
  • 5HAROUSSEAU JL. DEKKER AW, STAMATOULLAS-BASTARD A, et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B[J]. Antimicrob Agents Chemother, 2000, 44(7) : 1887-1893.
  • 6MORGENSTERN GR, PRENTICE AG, PRENTICE HG, et al.A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies[J]. Br J Haematol, 1999, 105(4):901-911.
  • 7WINSTON DJ, MAZIARZ RT, CHANDRASEKAR PH, et al.Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter,randomized trial[J]. Ann Intern Med, 2003, 138(9): 705-713.
  • 8MARR KA, CRIPPA F, LEISENRING W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants[J]. Blood, 2004, 103(4): 1527-1533.
  • 9GOTZSCHE PC, JOHANSEN HK, Routine versus selective antifungal administration for control of fungal infections in patientswith cancer[J]. Cochrane Database Syst Rev, 2002, (2):CD00-0026.
  • 10BOW E J, LAVERDIERE M, LUSSIER N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials[J]. Cancer,2002, 94(12) :3230-3246.

共引文献119

同被引文献18

引证文献3

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部